NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Morgan Stanley lowered the firm’s price target on Biohaven (BHVN) to $63 from $69 and keeps an Overweight rating on the shares. Biohaven ...

Principal Financial Group Inc. raised its holdings in Biohaven Ltd. (NYSE:BHVN – Free Report) by 4.4% in the 4th quarter, ...

Biohaven Ltd. (NYSE:BHVN – Get Free Report) fell 6.1% during mid-day trading on Monday after the company announced weaker ...

Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Acelyrin rejected a bid by Concentra and Atara cut staff.

Pomerantz LLP is investigating claims on behalf of investors of  Biohaven Ltd ("Biohaven" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

Media are invited to join the Honourable Diane Lebouthillier, Minister of Fisheries, Oceans and the Canadian Coast Guard and Member of Parliament for Gaspésie?Les Îles-de-la-Madeleine, on behalf of ...

Biohaven stock tumbled for the second day running Tuesday after its bipolar mania treatment failed in a three-week study.

Four Colorado physicians are named in a lawsuit settlement involving pharmaceutical company Biohaven, which allegedly paid ...

Biohaven in recent months has reported a clinical stumble in spinal muscular atrophy, alongside a Phase I readout for its ...

Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint in a pivotal Phase II/III bipolar trial, sinking ...

California Resources Corp.’s (CRC) shares plummeted 11.7% after posting fourth-quarter 2024 adjusted earnings per share of $0.91, missing the Zacks Consensus Estimate of $0.34. Shares of TG ...